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Basal cell carcinoma (BCC), the most common human cancer, undergoes spontaneous regression in certain
circumstances, which is potentially immune-mediated. To understand the immune response surrounding BCCs,
we characterized the genomic, protein, and cellular microenvironment associated with BCC in comparison to
normal skin. Our results demonstrated the following: (1) CD4þCD25þFoxp3þ surround epithelial tumor
aggregates; (2) Immature dendritic cells (DCs) were abundant in the tumor microenvironment; (3) BCC showed
increased expression of IL-4, IL-10, and CCL22 and increased expression of interferon-associated genes (IFI27,
IRF1, IRF7, and G1P2) and IL-12/23, gene indicating a Th2 dominant microenvironment. Our findings suggest a
dynamic state within the immune microenvironment associated with BCC. The finding of phenotypic T regs, in
conjunction with immature DCs and Th2 cytokines, suggests an attenuated state of immunity to human BCC. In
contrast, abundant CD8þ T cells, an interferon signal, and IL-12/23 suggest partial host antitumor response. A
better understanding of these opposing forces within the immune microenvironment may facilitate
development of more potent immune-based treatment for BCC and other human carcinomas.
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INTRODUCTION
Basal cell carcinoma (BCC) is the most common human
cancer affecting nearly one million patients in the United
States annually. It is usually characterized by slow growth
and low metastatic potential. However, if untreated or
incompletely treated, BCC results in massive local tissue
damage. Although the mainstay of therapy is surgical removal
with tumor-free margins, immune response modifiers, in-
cluding IFNa (Tucker et al., 2006) and imiquimod (Geisse
et al., 2004), have been used with varying degrees of success
(ranging between 75 and 96%). Immune responses within the
skin may be important in limiting the spread of cutaneous
tumors, and harnessing the potential for specific antitumor
immunity may be key in optimizing non-surgical approaches
to BCC therapy.
Excised BCCs display an inflammatory response with
cytotoxic T cells and dendritic cells (DCs) present (Azizi
et al., 1987). Local production of cytokines, including IFN-g,
IL-2, IL-10, transforming growth factor-b (TGF-b), and GM-
CSF, has been described (Kim et al., 1995; Wong et al.,
2000). The brisk inflammatory response coupled with the
inability to completely eradicate tumors, suggests a dynamic
state where immune stimulatory and immune suppressive
forces coexist and compete. With the recent use of immune
response modulators augmenting Th1 responses such as
topically applied imiquimod to treat BCCs, there is now
evidence that the immune system may be activated for
successful tumor eradication (Geisse et al., 2004; Wenzel
et al., 2005; Tucker et al., 2006). Imiquimod induces IFN-a
and Th1 cytokines including IL-12 (Stanley, 2002), results in
recruitment of plasmacytoid DCs expressing interferon-
associated genes (Urosevic et al., 2005), and induces
apoptosis in BCC (Schon et al., 2003). However, there are
many aspects of antitumor immunity in BCC that are not fully
characterized.
Quantitative analysis, precise localization, and phenotyp-
ing of the cells comprising the inflammatory infiltrate within
and surrounding BCCs, along with characterization of
immune response gene expression, is fundamental in estab-
lishing a baseline for designing and evaluating immunother-
apy and for determining the effects of immune suppression on
tumor behavior. We aimed to quantify, localize, and
phenotype the BCCs associated infiltrate and also evaluate
the expression of immune response genes in BCC. We have
determined the following: (1) CD4þ , CD25þFoxP3þ cells
(phenotypic T regs) surround BCC; (2) myeloid DCs but no
Langerhans cells were associated with BCC; (3) BCC was
characterized by a Th2 dominant microenvironment.
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RESULTS
Localization and characterization of the immune
microenvironment of BCC
We set out to define and precisely localize the cells that make
up the microenvironment surrounding BCC (Figure S1). The
regions examined within BCC samples were designated
tumor (T) and juxtatumoral dermis (JTD). Skin immediately
adjacent to tumors was analyzed, with regions designated as
non-lesional papillary dermis (NLPD) and non-lesional
epidermis (Figure S1). Normal skin from non-exposed areas
of healthy volunteers was designated normal epidermis and
normal papillary dermis (NPD). As BCC develops from basal
epidermis, we compared infiltrating leukocytes in normal
skin versus adjacent skin and tumor. We also compared NPD
versus NLPD and, JTD based on the structural similarities
between these regions.
The inflammatory infiltrate associated with BCCs was
characterized by significantly higher numbers of CD8þ cells
with lower numbers of Langerhans cells
Relatively, few CD3þ cells were found in NPD with
significantly higher numbers being demonstrated in NLPD
(Po0.01; Figure 1) and JTD (Po0.001; Figure 1). This was
mirrored by CD8þ cells, which were increased in NLPD
versus NPD and JTD (both Po0.04; Figure 1). DCs, while
capable of penetrating tumor nests, were predominantly
localized to JTD. The numbers of CD1aþ cells (Langerhans
cells) were significantly higher in the normal epidermis versus
the epidermis overlying the non-tumor bearing dermis from
BCC patients (Po0.0004; Figure 1). The numbers of
Langerhans cells were significantly lower in epithelial tumor
aggregates versus the epidermis overlying non-tumor bearing
dermis (Po0.00001). In contrast to T lymphocytes, CD11cþ
and CD1b/cþ cells showed relatively little change in JTD
when compared with NLPD (Figure 1). CD40þ , CD83þ , and
DC LAMPþ cells were absent in BCC (data not shown)
indicating a lack of mature DCs. Staining for CD4 on tissue
sections was not performed, as that marker appears on DCs as
well T-helper cells.
Phenotypic regulatory T cells surround BCC aggregates
We found that CD3þ and CD8þ T cells predominantly
aggregate in JTD. A progressive increase in T cells was
noticed within the respective dermal regions from NPD to
NLPD to JTD (Figure 1). To determine whether regulatory T
cells (T regs) might be associated with BCC, Foxp3þ cells
were quantified by immunohistochemistry (Figure 2a). There
were significantly increased numbers of Foxp3þ in the JTD
compared with NLPD (Po0.01) and NPD (Po0.0001). Triple
label IF confirmed the presence of CD4þCD25þFox P3þ
cells, which are phenotypically identical to regulatory T cells
(Figure 2b). Double label immunofluorescence was per-
formed to confirm that these Foxp3þ cells also expressed
CD3 (Figure 2c). Interestingly, CD3þ and CD8þ cells were
present not only in the JTD, but also in direct contact with the
tumor margins forming a ‘‘pseudocapsule’’ around the BCC
(Figure 2d). Foxp3þ T cells were detected in the pseudocap-
sular margins as well as penetrating the tumor nodules.
Genomic analysis of BCC microenvironment
We performed genomic analysis of BCC, adjacent non-tumor
bearing skin, and normal skin to assess differential expression
of immune response genes in BCC (Figure 3). We included
normal skin recognizing that the effects of UV exposure might
influence non-tumor bearing skin adjacent to excised BCC.
Microarray data showed increased expression of interferon-
associated genes, including IFI27, IRF1, IRF7 and G1P2 in
BCC versus normal skin. Angiogenesis-associated genes,
including CXCR4 and IL-1b, were upregulated in BCC versus
normal skin, whereas IL-6 and CXCL2 were upregulated in
non-tumor bearing skin adjacent to BCC compared with
normal skin. Expression of CXCL9, CCL2, CCL20, IL-4
receptor, and CD3D were increased in BCC versus normal
skin. Expression of CCL27 (CTACK) was highest in normal
skin and higher in peritumoral skin compared with BCC. Data
are summarized in Figure 3.
Differential expression of CXCL9, CXCL12, CCL15,
CCL27, IL-1b, and IL-6 was confirmed by reverse transcrip-
tase-PCR (RT-PCR) (Figure 4). In addition, RT-PCR analysis
showed increased expression of IL-4, IL-10, IL-CCL22, P19,
and P40 subunits of IL-23 were in BCC versus normal skin.
Tumor contained lower levels of IFN-g, TGF-b, and IL-17
compared with normal skin.
DISCUSSION
We have quantified and localized DCs and Foxp3þT cells
associated with BCC, and we have also performed compara-
tive genomic analysis of immune response genes in BCC
versus adjacent non-tumor bearing and normal skin. Several
findings stand out: (1) CD4þCD25þFox P3þ (phenotypic T
regs) surround epithelial aggregates of BCC; (2) BCC-
associated myeloid DCs are primarily immature; (3) there is
increased expression of IL-4, IL-10, CCL22, which favors a
Th2 environment and increased expression of interferon-
associated genes (IFI27, IRF1, IRF7 and G1P2) favoring Th1.
Current theories of carcinogenesis are evolving to explain
how cancer proceeds despite ‘‘immunosurveillance’’ (Zitvo-
gel et al., 2006). Although rarely completely effective, the
immune system is able to recognize and destroy cancer cells.
T cells, DCs, and their products appear to be involved in this
antitumor host response. However, the cancer cells may
develop mechanisms to subvert these effects. The end result
of this balance between host antitumor responses and tumor
survival tactics will either lead to tumor eradication (regres-
sion) or tumor growth. The data in our paper support this
concept. Interferon-associated genes represent an ongoing
antitumor response; T regs, immature DCs, and Th2 genes are
all features that would allow tumor survival.
T regs are recently described as T cells that appear to
control immune responses in an antigen-specific manner
(Rutella and Lemoli, 2004). Mediators responsible for T reg
development include IL-10 and TGF-b (Rutella and Lemoli,
2004). We found an upregulation of IL-10 but decreased
TGF-b mRNA. This combination may still be sufficient to
induce T regs, and the genomic levels of these cytokines may
not correlate directly with protein expression. In addition, the
chemokine responsible for T reg chemotaxis, CCL22, is also
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increased in BCC (Curiel et al., 2004; Lee et al., 2005; Yang
et al., 2006), suggesting a mechanism for T reg localization in
peri-tumoral areas. T regs appear to control autoimmunity
(Rutella and Lemoli, 2004), and may also suppress antitumor
responses (Beyer and Schultze, 2006; Beyer et al., 2006).
CD4þCD25þFoxp3þ T regs from ovarian carcinoma
patients suppressed tumor-specific T-cell immunity (Garcia-
Castro et al., 2001; Curiel et al., 2004). Studies have also
correlated higher T-reg cell frequencies in gastric carcinoma
patients with poorer prognosis and decreased survival rates
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Figure 1. Characterization of the microenvironment associated with BCC. Cell counts showed increased numbers of CD3þ and CD8þ T cells and decreased
numbers of CD1aþ Langerhans cells associated with BCC. Numbers of CD1b/cþ and CD11cþ were unchanged in non-lesional dermis versus JTD.
www.jidonline.org 2393
H G Kaporis et al.
Regulatory T cells are Associated with BCC
(Beyer and Schultze, 2006). In BCCs, the presence of Foxp3þ
cells surrounding the tumor nodules may attenuate the
function of DCs and cytotoxic T cells.
Mechanisms by which T regs suppress immunity in vivo
are poorly understood and may involve antigen-presenting
cells. T regs may impair DC maturation or suppress
expression of DC co-stimulatory molecules, and IL-10 may
be responsible for both these effects (Nestle et al., 1997;
Houot et al., 2006). This may be consistent with our findings,
which include increased IL-10 and immature DCs (CD40,
CD86, CD83, and DC LAMP). In addition, UV may also
induce IL-10 (Enk et al., 1995), which could contribute to this
effect. BCCs occur in sun-exposed areas, and thus the
potential effects of UV exposure on local DCs may also be
additive.
It is possible that immature DCs are involved in attenuat-
ing the immune response to BCC, and in our studies, the BCC
microenvironment was associated with high the number of
immature DCs. Immature DCs play a role in the induction of
peripheral T-cell tolerance (Steinman et al., 2003; Banerjee
et al., 2006). Tolerogenic DCs with a distinctive IL-10þ IL-
12 cytokine production profile have been described (Rutella
and Lemoli, 2004; Rutella et al., 2006a, ). A regulatory DC
subset, which secreted high levels of IL-10 and suppressed T-
cell proliferation in vitro and in vivo has also been described
(Tang et al., 2006). In addition, immature DCs may contribute
to tumor proliferation directly as immature DCs support
growth of human cutaneous T-cell lymphoma cells for
extended periods (Berger et al., 2002).
Another factor that could contribute to an immunosup-
pressive environment is the increased expression of Th2
cytokines. Although others have found a similar Th2 cytokine
profile in BCC (Kim et al., 1995), we confirm an increase in
IL-4, IL-10, but extend this to include CCL22 (MDC), which
may be chemotactic for Th2 cells (Vulcano et al., 2001).
In contrast to these potential tumor-permissive mechan-
isms discussed above, there may be concurrent immune
responses directed toward tumor eradication. Trafficking of
CD8þ cells to the JTD supports the potential for a specific
adaptive antitumor response. We found increased expression
of interferon-associated genes IFI27, IRF1, IRF7, and G1P2.
Other important cytokines that may be responsible for DC
activation were also increased in BCCs. P19 (a component of
IL-23) and p40 (shared subunit of IL-12 and IL-23) were both
elevated in BCC. IL-23 can enhance the proliferation of
memory T cells and production of IFN-g from activated T
cells, and can induce antitumor effects in vitro (Shan et al.,
2004, 2006). Similarly, IL-12 may activate DCs and mediate
Th1 antitumor immunity (Colombo and Trinchieri, 2002).
This is consistent with induction of IL-12 among other
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Figure 2. Phenotypic regulatory T cells are associated with human BCC. (a) Inflammatory cells form a ‘‘pseudocapsule’’ around the tumor nodule. Infiltrating
mononuclear cells (arrows). The interface of tumor (T)/stroma (S) (dashed lines). FoxP3þ cells were present in the ‘‘pseudocapsule’’ surrounding BCC. (b)
Double label immunofluorescence confirmed that FoxP3þ cells expressed CD3. (c) Triple label immunofluorescence showing CD4þCD25þFoxp3þ cells
associated with BCC. (d) Cell counts show increased numbers of Foxp3þ cells in JTD versus NLPD versus normal skin.
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cytokines during imiquimod treatment for BCC (Stanley,
2002).
In summary, our studies suggest a dynamic state within the
immune microenvironment associated with BCC. The finding
of phenotypic T regs in conjunction with immature DCs and
Th2 cytokines suggests an attenuated state of immunity to
human BCC. In contrast, abundant CD8þ T cells, an interferon
signal, and IL-12/23 suggest partial host antitumor response.
Further understanding of the interplay between these forces may
facilitate the development of rationally based immune therapy
for BCC and other human skin cancers.
MATERIALS AND METHODS
Institutional Review Board approval was obtained before enrolling
patients to participate in this study. Informed consent was obtained
from patients before their participation, and the study was performed
with strict adherence to the Declaration of Helsinki Principles.
Samples used in study For IHC
Twenty nodular BCC samples were obtained during Mohs
micrographic surgery. Tumors were obtained from head and
neck (11/20), trunk (2/20), and extremities (7/20), respectively.
Additionally, 10 normal specimens were obtained via 3-mm
punch biopsies from non-sun exposed areas of patients without skin
tumor.
For Microarray and RT-PCR
Ten paired samples of tumor and site-matched normal skin were
obtained during surgery. Site-matched normal skin was obtained
from site-matched uninvolved skin at the time of repair after clear
margins were achieved. Mean age of patients with BCC in this study
was 73 years (range: 46–83). Mean tumor size 1.0 0.8 cm. Average
final tumor defect after clearing tumors was 1.9 1.8 cm. All tumors
with one exception were located on sun-exposed areas. For genomic
studies on normal skin, 10 normal specimens were obtained via
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Figure 3. Expression profiling for immune response genes in BCC, adjacent non-tumor bearing skin, and normal skin. Gene array analysis of mRNA from nine
basal cell carcinoma (BCC), nine site-matched, patient-matched, non-tumor bearing skin (PT), and 10 normal skin samples (N). mRNA was hybridized to
individual oligonucleotide arrays containing B12,000 human genes (HG-U95A/Av2 chips). Heat map shows unsupervised, hierarchical clustering for gene
expression differences that are statistically significant (Po0.05, after correction for multiplicity). Fold changes (FC) shown for BCC versus normal (BCC/N), BCC
versus adjacent non-tumor bearing skin (BCC/PT), (adjacent non-tumor bearing skin vs BCC (PT/BCC), and adjacent non tumor bearing skin versus normal skin
(PT/N). (a) Genes differentially expressed in BCC versus peritumoral skin or normal skin. (b) Genes differentially expressed in peritumoral skin versus BCC or
normal skin.
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3-mm punch biopsies from non-sun exposed areas of patients
without skin cancer.
Immunohistochemistry
Frozen tissue sections were stained with hematoxylin (Fisher, Fair
Lawn, NJ) and eosin (Shandon, Pittsburgh, PA) and with purified
mouse anti-human monoclonal antibodies to CD1b/c (Biosource,
Camarillo, CA; diluted 1/100), CD11c, CD1a, CD8, CD3, CD83,
CD40, CD16, CD25, CD40, and HLADR (BD Pharmingen, San
Diego, CA; all diluted 1/100 except CD40 (1/50) and HLADR (1/
200), Langerin, DC-LAMP (Immunotech, Cedex, France; (1/50),
CD86 (Genetex, San Antonio, TX; diluted 1/100), CTACK/CCL27
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Figure 4. Real time RT-PCR analysis of selected genes in BCC and normal skin. Mean values of gene expression for selected genes are graphically represented
after normalization of expression using gene to HARP mRNA. mRNA was analyzed from BCC specimens (BCC) and normal skin (N) (n¼ 9 for each). IL-4, IL-10,
P19, P40, CXCL9, and CCL22 were increased in BCC. IFNg, TGF-b, IL-6, IL1b, IL-17, CXCL12, and CCL27 were decreased in BCC.
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(R&D Systems, Minneapolis, MN; diluted 1/500), Foxp3 (Abcam,
Cambridge, MA diluted 1/40). Biotin-labeled horse anti-mouse
antibody (Vector Laboratories, Burlingame, CA) was amplified with
avidin–biotin complex (Vector Laboratories) and developed with
chromogen 3-amino-9-ethylcarbazole (Sigma Aldrich, St Louis,
MO). Counterstaining was performed with light green (Sigma
Aldrich). Appropriate isotype controls were performed with each
immunohistochemistry experiment.
Image analysis
Tumor-bearing skin and non-tumor bearing skin adjacent to excised
tumor, and normal skin from volunteers were evaluated for the
expression of a wide panel of surface markers by immunohisto-
chemistry and immunofluorescence. The regions examined within
BCC samples were designated tumor (T), JTD, NLPD and non-
lesional epidermis. The regions examined within normal skin
included normal epidermis and NPD. NPD, NLPD, and JTD were
compared in this study based on the structural similarities between
these regions. Positive cells were counted manually, and area
measures were computed by computer-assisted image analysis,
National Institutes of Health software (NIH IMAGE 6.1). Cell counts
per mm2 were determined within normal and non-lesional epidermis,
papillary dermis (100mm deep to the epidermis), BCC epithelial
aggregates, and JTD (100 mm circumferential to tumor). In all cases,
tumor sections with the most brisk response were selected for
analysis.
Statistical analysis
Statistical comparisons of cell counts were performed using a two-
tailed, Student’s t-test, with Po0.05 considered significant.
RNA preparation
The total RNA was processed as described previously (Haider et al.,
2006). Briefly, the microarrays used for this study were U95A-set
GeneChip probe arrays (Affymetrix Inc., Santa Clara, CA) containing
probe sets of approximately 12,000 genes. The labeled target was
fragmented, and hybridized to probe arrays as described previously
(Zhou et al., 2003). Briefly, total RNA was extracted from tissues
frozen in liquid nitrogen using the RNeasy Mini Kit (Qiagen,
Valencia, CA). DNA was removed with on-column DNAse digestion
by Qiagen RNAse-free DNAse Set. Total RNA (B4 mg) was reverse-
transcribed, amplified, and labeled. mRNA was isolated and
converted to double-strand cDNA and then to biotinylated cRNA
(BioArray High Yield RNA Transcription Labeling Kit; Enzo Biochem
Inc., Farmingdale, NY). After fragmentation and quality confirmation
with Affymetrix Test-3 Array, 15 mg of the biotinylated cRNA were
hybridized to Affymetrix Human Genome U95A GeneChips (12,000
probe sets) (Affymetrix Inc.). The chips were washed, stained with
streptavidin–phycoerythrin and, scanned (HP GeneArray Scanner,
Hewlett–Packard Company, Palo Alto, CA). On each chip, the
human housekeeping genes b-actin and GAPDH served as controls.
Suite 5.0 software normalized the expression level values using these
controls. Chips with 30 to 50 ratios for GAPDH less than 3 and scaling
factor within threefold of each other were compared for the study.
Microarray analysis
To obtain a list of biologically most interesting genes used in this
study, multiple statistical analyses were performed. Statistical
comparisons of expression levels pairwise between each condition
(BCC, NT, and N) were performed by using Gene Spring Software.
On the basis of full data set, paired t-tests were performed to assess
the interesting genes for the distinction. Owing to the multiple testing
problems encountered in the analysis of microarray data, we chose
to declare those genes with a false discovery rate of at most 5% as
having a significant effect. In this study, genes that passed the
Benjamini–Hochberg criterion were considered. A list of significantly
regulated immune response genes (Benjamini–Hochberg false discov-
ery rate 5%) is presented as up- or downregulated greater than twofold
based on the average of eight patients (BCC vs N, BCC vs NT).
Expression changes with real-time RT-PCR analysis of tissue
mRNA gene expression
TaqMan RT-PCR assays were generated with the Assay on Demand
primers and probes for P19, P40, IL-1b, IL-6, IL-4, IL-10, IL-17, IFN-g,
TGF-b, CCL 20 (MIP3a), CCL27 (CTACK), CXCL12, CXCL9, and CCL22
designed by Applied Biosystem (Foster City, CA). The RT-PCR reaction
was performed using EZ PCR Core Reagents (Applied Biosystems)
according to the manufacturer’s directions. The samples were amplified
and quantified on an Applied Biosystems PRISM 7700 using the
following thermal cycler conditions: 2minutes at 501C; 30minutes at
601C; 5minutes at 951C; and 40 cycles of 15 seconds at 951C followed
by 60seconds at 601C. The human acidic ribosomal protein (HARP)
gene, a housekeeping gene, was used to normalize each sample and
each gene. Primer sequences HARP-forward, CGCTGCTGAACATGCT
CAA; HARP-reverse, TGTCGAACACCTGCTGGATG; HARP-probe, 6-
FAM-TCCCCCTTCTCCTTTGGGCTGG-TAMRA (GenBank accession
no. NM-001002) were used. The data were analyzed and samples
quantified by the software provided with the Applied Biosystems PRISM
7700 (Sequence Detection Systems, version 1.7).
Statistical analysis
Statistical comparisons of mRNA expression level was performed
using a two-tailed, Student’s t-test, with Po0.05 considered
significant.
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